TNFRSF8 expression
|
Peripheral T-cell Lymphoma
|
TNFRSF8 expression
|
Peripheral T-cell Lymphoma
|
brentuximab vedotin Sensitive: A1 - Approval
|
brentuximab vedotin Sensitive: A1 - Approval
|
TNFRSF8 expression
|
T Cell Non-Hodgkin Lymphoma
|
TNFRSF8 expression
|
T Cell Non-Hodgkin Lymphoma
|
brentuximab vedotin Sensitive: B - Late Trials
|
brentuximab vedotin Sensitive: B - Late Trials
|
TNFRSF8 expression
|
AML
|
TNFRSF8 expression
|
AML
|
brentuximab vedotin Sensitive: C1 - Off-label
|
brentuximab vedotin Sensitive: C1 - Off-label
|
TNFRSF8 expression
|
Cutaneous T-cell Lymphoma
|
TNFRSF8 expression
|
Cutaneous T-cell Lymphoma
|
brentuximab vedotin Sensitive: C1 - Off-label
|
brentuximab vedotin Sensitive: C1 - Off-label
|
TNFRSF8 expression
|
Diffuse Large B Cell Lymphoma
|
TNFRSF8 expression
|
Diffuse Large B Cell Lymphoma
|
rituximab + brentuximab vedotin Sensitive: C3 – Early Trials
|
rituximab + brentuximab vedotin Sensitive: C3 – Early Trials
|
TNFRSF8 expression
|
Peripheral T-cell Lymphoma
|
TNFRSF8 expression
|
Peripheral T-cell Lymphoma
|
CHEP-BV Sensitive: C3 – Early Trials
|
CHEP-BV Sensitive: C3 – Early Trials
|